NCT01892540

PET/CT or PET/MRI in Measuring Tumors in Patients Undergoing Clinical Imaging or With Newly Diagnosed Breast Cancer

Positron Mammographic Imaging (PMI)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 43 (actual)
• Sponsor: Case Comprehensive Cancer Center · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial studies positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) in measuring tumors in patients undergoing clinical imaging or with newly diagnosed breast cancer. New diagnostic procedures, such as PET/CT or PET/MRI, may be more effective than MRI alone in measuring tumors in patients undergoing clinical imaging or with newly diagnosed breast cancer.

Detailed description

PRIMARY OBJECTIVES: I. To improve visualization of tumors by developing better image reconstruction and correction methods. II. To revise the positioning devices and, if necessary, scanner table to fit a wider size range of women. OUTLINE: Patients undergo clinical fludeoxyglucose F-18 (FDG)-PET/CT followed by prone breast PET/CT and/or prone breast PET/MRI with or without gadopentetate dimeglumine (DTPA).

Conditions

• Breast Cancer
• Unspecified Adult Solid Tumor, Protocol Specific

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	positron emission tomography/computed tomography	Undergo PET/CT
DIAGNOSTIC_TEST	PET/MRI	Undergo PET/MRI positron emission tomography/magnetic resonance imaging hybrid imaging
DEVICE	Position Device

Timeline

• Start date: 2013-05-01
• Primary completion: 2015-06-01
• Completion: 2015-06-01
• First posted: 2013-07-04
• Last updated: 2020-03-04
• Results posted: 2020-02-25

Locations

1 site across 1 country: United States